NERVGEN PHARMA CORP.

Pre-revenue clinical-stage pharma with bottom-decile returns and limited cash, no posted trial readout to de-risk it.

Strengths

• Net loss narrowed sharply year-over-year (net income growth 83rd pct)
• Newly public Nasdaq listing provides capital-markets access

Risks

• Deeply negative ROE (-12.7, 1st pct) and ROA (-1.9, 12th pct) typical of cash-burning biotech
• Modest cash ($16M, 31st pct) and thin current ratio (1.16) against ongoing R&D burn